IL1B and atherosclerosis: Currently, the hunt to target the inflammatory response in atherosclerosis has accelerated after the positive results of the CANTOS trial, which tested the use of canakinumab (neutralizing anti-IL1β) to treat high-risk atherosclerotic patients with prior MI.